Jazz Pharmaceuticals Ireland

Company snapshot

Jazz Pharmaceuticals Ireland maintains 208 tracked programs across Acute Myeloid Leukemia, Narcolepsy, Epilepsy, Acute Lymphoblastic Leukemia, Fibromyalgia, Autism Spectrum Disorder, Essential Tremor, Diffuse Intrinsic Pontine Glioma, Multiple Sclerosis, Pain, Schizophrenia, Advanced Solid Tumor. Momentum score: 20/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinical trial

• 10 approved product(s) across US/EU regulatory metadata.
• 208 active pipeline program(s) linked via ClinicalTrials.gov.
• 89 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Jazz Pharmaceuticals Ireland. Not investment advice.

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 50

• Peer + 0 momentum

  Ultragenyx UK

  TA overlap score 40

• Peer + 0 momentum

  Indivior Pty

  TA overlap score 27.8

• Peer + 0 momentum

  ADC Therapeutics

  TA overlap score 26

• Peer + 0 momentum

  Axsome Therapeutics

  TA overlap score 25.6

• Peer + 0 momentum

  Kura Oncology

  TA overlap score 25

• Peer + 0 momentum

  H. Lundbeck A/S

  TA overlap score 23.4

• Peer + 0 momentum

  Amneal Pharma Europe

  TA overlap score 23

• Peer + 0 momentum

  Prelude Therapeutics

  TA overlap score 22.6

• Peer + 0 momentum

  AB Science

  TA overlap score 21.2

Recent activity

Latest pipeline, patent, and corporate events for Jazz Pharmaceuticals Ireland.

1. Jun 8, 2026 Clinical update

   ZWI-ZW25-301 — Phase 3

2. Jun 8, 2026 Clinical update

   ZWI-ZW25-202 — Phase 2

3. Jun 8, 2026 Clinical update

   JZP598-303 — Phase 3

4. Jun 8, 2026 Clinical update

   JZP598-302 — Phase 3

5. Jun 8, 2026 Clinical update

   EmpowHER 208 — Phase 2

View all clinical trial activity →

• What is Jazz Pharmaceuticals Ireland?

  Jazz Pharmaceuticals Ireland is a pharma organization headquartered in Dublin, IE. It trades on NYSE under ticker JAZZ. Primary therapeutic focus areas include Acute Myeloid Leukemia, Narcolepsy, Epilepsy, Acute Lymphoblastic Leukemia, Fibromyalgia. NovaPharmaNews links 208 clini

• Is Jazz Pharmaceuticals Ireland publicly traded?

  Yes. Jazz Pharmaceuticals Ireland is listed with ticker JAZZ on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Jazz Pharmaceuticals Ireland develop or market?

  We link 91 drug profile(s) where Jazz Pharmaceuticals Ireland is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/jazz-pharmaceuticals-plc#company-drugs.

• What are the latest developments for Jazz Pharmaceuticals Ireland?

  In the last 12 months our linked public records show 208 trial program update(s) and 9 US patent grant(s) tied to this profile.

• What therapeutic areas does Jazz Pharmaceuticals Ireland focus on?

  Jazz Pharmaceuticals Ireland focuses on Acute Myeloid Leukemia, Narcolepsy, Epilepsy based on our analysis of their pipeline programs and drug development activities.